Aprepitant [aprepitant]
- Terms
-
3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-on
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)fenyl]ethoxy]-3-(4-fluorofenyl)-4-morfolinyl]
Emend
-
(1-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine
(2R)-(1R)-3,5-bis(Trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine
Emend
L 754,030
L 754030
L-754,030
L-754030
MK 0517
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK0517
A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.
- DUI
- D000077608 MeSH Browser
- CUI
- M0447596
- CAS
- 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,4-dihydro-
- History note
- 2019 (1998)
- Public note
- 2019; APREPITANT was indexed under MORPHOLINES 1998-2018
Allowable subheadings
- AD
- administration & dosage 2
- AE
- adverse effects 0
- AG
- agonists 0
- AA
- analogs & derivatives 0
- AN
- analysis 0
- AI
- antagonists & inhibitors 0
- BL
- blood 0
- CF
- cerebrospinal fluid 0
- CS
- chemical synthesis 0
- CH
- chemistry 0
- CL
- classification 0
- EC
- economics 0
- HI
- history 0
- IM
- immunology 0
- IP
- isolation & purification 0
- ME
- metabolism 0
- PK
- pharmacokinetics 0
- PD
- pharmacology 1
- PO
- poisoning 0
- RE
- radiation effects 0
- ST
- standards 0
- SD
- supply & distribution 0
- TU
- therapeutic use 1
- TO
- toxicity 0
- UR
- urine 0